Are IDH mutations good minimal residual disease (MRD) markers in acute myeloid leukemia (AML)?
Developing an understanding of disease progression in MDS and AML
Cytokine release syndrome: a limiting factor for AML treatment
Waldenström’s macroglobulinemia: Treatment methods and clonal evolution
Targeted molecular signatures of DLBCL and upcoming CheckMate 647 trial for PCNSL and PTL